Vol 6 | Issue 1 | January-June 2025 | Page 15-19 | Bhuvaneswari Balasubramanian, Sandeep Diwan
DOI: https://doi.org/10.13107/ijra.2025.v06.i01.116
Open Access License: CC BY-NC 4.0
Copyright Statement: Copyright © 2025; The Author(s).
Submitted: 24-02-2025; Reviewed: 19-03-2025; Accepted: 19-05-2025; Published: 10-06-2025
Authors: Bhuvaneswari Balasubramanian [1]
Sandeep Diwan [2]
[1] Department of Anaesthesiology & Critical Care, AIIMS, Nagpur, Maharashtra, India.
[2] Department of Anaesthesiology, Sancheti Hospital, Pune, Maharashtra, India.
Address of Correspondence
Dr. Bhuvaneswari Balasubramanian
Department of Anaesthesiology & Critical Care, AIIMS, Nagpur, Maharashtra, India.
Email: docbhuvaneswari@gmail.com
Abstract
Interindividual variability in analgesic response reflects heritable differences in drug metabolism, receptor expression, neurotransmitter turnover, and central nervous system drug transport. Pharmacogenomic advances have clarified functional consequences of polymorphisms in CYP2D6, CYP3A4, UGT2B7, OPRM1, COMT, and ABCB1, each of which influences opioid and non-opioid pharmacokinetics and pharmacodynamics. CYP2D6 metabolizer status determines conversion of prodrugs such as codeine and tramadol to active metabolites, while CYP3A4 variation modulates systemic opioid clearance. OPRM1 A118G alters μ-opioid receptor binding affinity and signaling, COMT Val158Met influences catecholamine-mediated pain sensitivity, and ABCB1 variants affect opioid penetration across the blood–brain barrier. Clinical studies demonstrate genotype-associated differences in analgesic efficacy and toxicity, though effect sizes vary across populations and analgesic classes. Implementation remains constrained by limited genotype-stratified randomized trials, testing turnaround time, unclear cost-effectiveness, and underrepresentation of Asian and Southeast Asian ancestry groups in genomic datasets. This mini-review synthesizes mechanistic foundations, clinical evidence, population variation, and practical considerations for integrating pharmacogenomics into perioperative and chronic pain management.
Keywords: Genomics, Pharmacogenetics, Precision medicine, Analgesia, CYP2D6, Postoperative pain, Opioids
References
1. Kaye AD, Mahakian T, Kaye AJ, Pham AA, Hart BM, Gennuso S, Cornett EM, Gabriel RA, Urman RD. Pharmacogenomics, precision medicine, and implications for anesthesia care. Best Pract Res Clin Anaesthesiol. 2018;32(2):61–81. doi:10.1016/j.bpa.2018.06.002
2. Crews KR, Monte AA, Huddart R, Caudle KE, Kharasch ED, Gaedigk A, et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy. Clin Pharmacol Ther. 2021;110(4):888–896. doi:10.1002/cpt.2391
3. Gong L, Whirl-Carrillo M, Klein TE. PharmGKB: An integrated resource of pharmacogenomic knowledge. Curr Protoc. 2021;1(8):e226. doi:10.1002/cpz1.226
4. Baber M, Chaudhry S, Kelly L, Ross C, Carleton B, Koren G. Pharmacogenetics of codeine analgesia in the postpartum period. Pharmacogenomics J. 2015;15(5):430–435. doi:10.1038/tpj.2014.80
5. Maulana Y, Toro Jimenez R, Twesigomwe D, Sani L, Irwanto A, Bertin N, Gonzalez-Porta M. The variation landscape of CYP2D6 in a multi-ethnic Asian population. Scientific Reports. 2024 Jul 20;14(1):16725.
6. Bagher AM, Hareeri RH. Allele frequency and genotype distribution of the opioid receptor μ-1 (OPRM1) A118G polymorphism in the Western Saudi population. Journal of Applied Biomedicine. 2023 Sep 22;21(3):160-5.
7. Zhang X, Liang Y, Zhang N, Yan Y, Liu S, Fengxi H, Zhao D, Chu H. The relevance of the OPRM1 118A> G genetic variant for opioid requirement in pain treatment: a meta-analysis. Pain physician. 2019;22(4):331.
8. Wu SB, Cai LN, Yang XH, Fu HG, Sun K, Yuan F, Dong TL. Impact of CYP2D6 polymorphisms on postoperative fentanyl analgesia in gastric cancer patients. Genet Test Mol Biomarkers. 2015;19(5):248–252. doi:10.1089/gtmb.2014.0230
9. Ferreira do Couto ML, Fonseca S, Pozza DH. Pharmacogenetic approaches in personalized medicine for postoperative pain management. Biomedicines. 2024;12(4):729. doi:10.3390/biomedicines12040729
10. Dib P, Tung SR, Dib SA, Hamdy A, Kitzmiller JP. Pharmacogenomics applications in perioperative medicine. J Transl Sci. 2018;4(5):1–6. doi:10.15761/JTS.1000280
11. Dzierba AL, Stollings JL, Devlin JW. Precision medicine in analgesia and sedation for critically ill adults: a pharmacogenetic approach. Pharmacotherapy. 2023;43(11):1154–1165. doi:10.1002/phar.2850
12. Smith DM, Stevenson JM, Ho TT, Formea CM, Gammal RS, Cavallari LH. Pharmacogenetics in opioid stewardship. J Am Coll Clin Pharm. 2022;5(2):239–250. doi:10.1002/jac5.1616
13. Reizine N, Danahey K, Schierer E, Liu P, Middlestadt M, Ludwig J, et al. CYP2D6 phenotype and pain control among opioid-treated oncology patients. Oncologist. 2021;26(11):e2042–e2052. doi:10.1002/onco.13873
14. Theken BD, Lee CR, Gong L, et al. CPIC guideline for CYP2C9 genotype and NSAID therapy. Clin Pharmacol Ther. 2020;108(3):414–421. doi:10.1002/cpt.1830
15. Verbelen M, Weale ME, Lewis CM. Cost-effectiveness of pharmacogenetic-guided treatment: are we there yet?. The pharmacogenomics journal. 2017 Oct;17(5):395-402.
16. Agulló, L., Aguado, I., Muriel, J., Margarit, C., Gómez, A., Escorial, M., Sánchez, A., Fernández, A. and Peiró, A.M., 2023. Pharmacogenetic guided opioid therapy improves chronic pain outcomes and comorbid mental health: a randomized, double-blind, controlled study. International Journal of Molecular Sciences, 24(13), p.10754.
17. Chen J, Li L, Chen SR, Chen H, Xie JD, Sirrieh RE, MacLean DM, Zhang Y, Zhou MH, Jayaraman V, Pan HL. The α2δ-1-NMDA receptor complex is critically involved in neuropathic pain development and gabapentin therapeutic actions. Cell reports. 2018 Feb 27;22(9):2307-21.
18. Dickens D, Webb SD, Antonyuk S, Giannoudis A, Owen A, Rädisch S, Hasnain SS, Pirmohamed M. Transport of gabapentin by LAT1 (SLC7A5). Biochemical pharmacology. 2013 Jun 1;85(11):1672-83.
19. Yeo J, Sia AT, Sultana R, Sng BL, Tan EC. Analysis of SCN9A gene variants for acute and chronic postoperative pain and morphine consumption after total hysterectomy. Pain Medicine. 2020 Nov;21(11):2642-9.
20. Andersson ML, Møller AM, Wildgaard K. Butyrylcholinesterase deficiency and its clinical importance in anaesthesia: a systematic review. Anaesthesia. 2019 Apr;74(4):518-28.
21. Jhun EH, Apfelbaum JL, Dickerson DM, Shahul S, Knoebel R, Danahey K, Ratain MJ, O’Donnell PH. Pharmacogenomic considerations for medications in the perioperative setting. Pharmacogenomics. 2019 Jul 1;20(11):813-27.
| How to Cite this Article: Balasubramanian B, Diwan S. Genomics and Precision Analgesia – Is This the Era? International Journal of Regional Anaesthesia. January-June 2025; 6(1): 15-19. DOI: https://doi.org/10.13107/ijra.2025.v06.i01.116 |
